Borage oil GLA for atopic dermatitis: where the evidence collapsed

Borage seed oil is one of the richest natural sources of gamma-linolenic acid (GLA), and for two decades it was a leading complementary therapy for eczema. The two largest double-blind trials and a Cochrane review then converged on a less flattering conclusion: GLA from borage or evening primrose oil does not meaningfully improve atopic dermatitis. The story is a useful case study in how mechanism-driven hype outruns trial data.

The mechanism that looked promising

Borage oil contains roughly 20–26% GLA, an omega-6 fatty acid that bypasses the delta-6-desaturase enzyme. Researchers in the 1980s observed that some atopic dermatitis patients had low delta-6-desaturase activity, suggesting that supplementing GLA might restore membrane fatty acid composition, reduce inflammatory eicosanoid signaling, and improve skin barrier function. Early small, often industry-sponsored trials reported eczema improvements, which built the commercial category.

What the larger trials showed

The BAMSE-cohort-era trials in the late 1990s and 2000s repeatedly failed to reproduce the effect. A multicenter UK trial of 140 atopic dermatitis patients randomized to borage oil 920 mg GLA daily for 24 weeks found no significant difference from placebo on SCORAD or itch scales [1]. A second UK trial in adults and children with eczema also found no benefit [2]. A separate trial of evening primrose oil GLA in 39 children with atopic eczema similarly found no significant effect [3].

The Cochrane verdict

The 2013 Cochrane review of oral evening primrose oil and borage oil for eczema pooled 27 trials and concluded that neither agent produced clinically meaningful effects on eczema symptoms versus placebo [4]. The conclusion stood across both adult and pediatric populations, and across both subjective patient-rated and physician-rated outcomes.

Why the early signal evaporated

Smaller trials with positive results were generally industry-funded or used selected populations. Once larger, independent trials were run with adequate blinding, treatment-allocation concealment, and intention-to-treat analyses, the effect dissolved. The pattern is similar to several other 'plausible mechanism, small positive trials' stories that did not survive replication.

Other proposed uses of GLA

Some evidence has been generated for GLA in rheumatoid arthritis tender-joint scores, diabetic neuropathy, and cyclical mastalgia, but effect sizes are small and replication is patchy. The mastalgia indication, once routine in some UK clinics, was de-recommended after randomized data did not support routine use [5]. None of these indications has a stronger evidence base than the atopic dermatitis one had at its peak.

Safety

Borage oil is generally well tolerated at typical doses. The relevant safety concern is the presence of pyrrolizidine alkaloids (PAs) in the seed and seed oil. Reputable manufacturers test for and remove PAs to below detection limits; cheaper preparations may not. Bleeding-risk interactions with anticoagulants are theoretical but rarely material at supplement doses.

The bottom line

Borage oil GLA does not improve atopic dermatitis in adults or children based on the largest randomized trials and a Cochrane review. Patients seeking dietary support for skin inflammation are better served by emollient therapy, dietary omega-3 from fish or algal sources where indicated, and standard topical treatment plans.